Related Experiment Video
Updated: Jan 7, 2026

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
GATOR1 complex controls cisplatin sensitivity
Zhenrui Pan1,2, Hanxiao Zhang1, Xia Xiao1
1CNRS UMR9018, Université Paris-Saclay, Gustave Roussy, Villejuif, France.
Abstract:
Cisplatin administration is the primary chemotherapy approach for many epithelial cancers. However, resistance to this drug poses a significant challenge to effective treatment. Despite the identification of numerous factors associated with resistance, reliable biomarkers predicting drug response remain elusive. Previously, low expression of the NPRL2 tumor suppressor was linked to cisplatin resistance. NPRL2, along with NPRL3 and DEPDC5, forms the GATOR1 complex, an upstream regulator of the mTORС1, the function of which is perturbed in many cancers, particularly those resistant to cisplatin. Here, we compare non-cancerous bronchial epithelium BEAS-2B cells with GATOR1 deletions, serving as a model of intrinsic cisplatin resistance, with non-small cell lung cancer lines A549, H460, and H1975 with acquired resistance to the drug. We found that deletion of any GATOR1 member, not solely NPRL2, promotes cisplatin resistance, whereas their overexpression renders cells sensitive to the drug. In cells with GATOR1 deletions, expression of the ATP7A transporter required for cisplatin efflux is increased, while expression of cisplatin influx transporters CTR2 and LRRC8A is downregulated, especially after treatment with the drug. This hinders drug accumulation in cells, resulting in the formation of fewer cisplatin-DNA adducts. Simultaneously, these cells exhibit enhanced DNA damage response and mTORC1 activity. Overexpression of GATOR1 components and/or concomitant treatment with an mTORC1 inhibitor restores sensitivity to cisplatin. Transcriptomic analysis of GATOR1-deleted BEAS-2B cells, treated or not with the drug, identifies new signatures important for understanding GATOR1 function and its role in cisplatin resistance. Thus, GATOR1 not only participates in the cellular response to amino acid availability but also plays a role in resistance to DNA-damaging anticancer drugs. This novel function of GATOR1 should be taken into account when developing new strategies to combat chemoresistance.
Insights
The GATOR1 complex, not just NPRL2, is crucial for cisplatin resistance in cancers. Deleting GATOR1 components increases resistance, while overexpression restores sensitivity, offering new therapeutic targets for chemotherapy resistance.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Cisplatin is a key chemotherapy for epithelial cancers, but drug resistance is a major obstacle.
- Low NPRL2 expression was previously linked to cisplatin resistance.
- NPRL2, NPRL3, and DEPDC5 form the GATOR1 complex, regulating mTORC1, which is often dysregulated in cisplatin-resistant cancers.
Purpose of the Study:
- To investigate the role of the GATOR1 complex in cisplatin resistance beyond NPRL2.
- To compare intrinsic and acquired cisplatin resistance models.
- To identify molecular mechanisms underlying GATOR1-mediated cisplatin resistance.
Main Methods:
- Utilized BEAS-2B cells with GATOR1 deletions as an intrinsic resistance model.
- Employed cisplatin-resistant non-small cell lung cancer cell lines (A549, H460, H1975) for acquired resistance.
- Analyzed transporter expression (ATP7A, CTR2, LRRC8A), DNA damage response, mTORC1 activity, and performed transcriptomic analysis.
Main Results:
- Deletion of any GATOR1 component confers cisplatin resistance; overexpression restores sensitivity.
- GATOR1 deletion upregulates cisplatin efflux (ATP7A) and downregulates influx (CTR2, LRRC8A) transporters.
- Cells with GATOR1 deletions show increased DNA damage response and mTORC1 activity, hindering cisplatin-DNA adduct formation.
Conclusions:
- The GATOR1 complex, not solely NPRL2, plays a significant role in both intrinsic and acquired cisplatin resistance.
- Altering GATOR1 component expression or inhibiting mTORC1 can modulate cisplatin sensitivity.
- GATOR1's novel function in chemoresistance warrants consideration for developing new therapeutic strategies against cisplatin resistance.
Related Concept Videos
Treatment Resistant Cancers
Negative Regulator Molecules
Inhibition of Cdk Activity

